Updated July 2026 · 9 min read

Malignant Hyperthermia for ICU Nurses 2026

Part of the ICU Emergencies Hub — browse every related guide in one place.

Malignant hyperthermia (MH) is rare, fast, and lethal — a genetic reaction to specific anesthetic drugs that turns skeletal muscle into a runaway furnace. It's classically an OR and PACU event, but ICU nurses recover these patients, care for the post-crisis phase, and need to recognize a late or recrudescent reaction. When MH hits, it is a drop-everything, all-hands emergency with one specific antidote: dantrolene, given fast.

The mechanism

MH is a genetic disorder (most often of the ryanodine receptor, RYR1) of the calcium-release channel in skeletal muscle. Expose a susceptible person to a triggering agent and that channel opens uncontrollably, flooding the muscle cell with calcium. The muscle contracts and metabolizes without pause, generating enormous heat, consuming oxygen, producing CO2 and acid, and breaking down — releasing potassium and setting off rhabdomyolysis. It's a hypermetabolic chain reaction, which is why the CO2 and the acidosis show up before the temperature.

The triggers — and the safe drugs

A personal or family history of an anesthetic problem — unexplained intraoperative death, a "reaction to anesthesia," or a known MH-susceptible relative — is a red flag that belongs in every pre-op and ICU handoff.

Recognizing the crisis

The earliest and most sensitive sign is an unexplained rise in end-tidal CO2 (in a ventilated patient) that doesn't respond to increasing ventilation — a reflection of the hypermetabolic state. Other early findings include tachycardia, masseter (jaw) rigidity after succinylcholine, and generalized muscle rigidity. The dramatic hyperthermia — temperatures that can rise very rapidly — is often a later sign, which is exactly why waiting for the fever costs lives. Labs show a mixed acidosis, hyperkalemia, and a rising CK; the urine may turn dark from myoglobin.

The response — dantrolene now

MH treatment is a coordinated sprint. The core steps: stop the triggering agent and switch to a safe anesthetic/technique; hyperventilate with 100% oxygen to blow off CO2; and give dantrolene immediately, repeated until the crisis resolves. Dantrolene works by blocking the abnormal calcium release, directly shutting off the runaway muscle metabolism — it is the only drug that treats the cause.

Alongside dantrolene: cool the patient aggressively (cold IV fluids, surface cooling, cooling the body cavities per protocol — and stop cooling before overshoot into hypothermia). Treat the hyperkalemia that can cause fatal arrhythmias — calcium, insulin/dextrose, and the rest of the stack. Correct the acidosis with ventilation and, as needed, bicarbonate. Treat arrhythmias per ACLS but avoid calcium channel blockers, which can interact dangerously with dantrolene. Push fluids and follow urine output to protect the kidneys from myoglobin. Call the MH Hotline for expert guidance if your facility uses it.

After the crisis

MH doesn't fully end when the temperature comes down. Patients are monitored in the ICU because recrudescence (a return of the crisis) can occur in the hours afterward, so dantrolene is often continued and the patient is watched for the return of rising CO2, rigidity, or fever. The aftermath includes managing rhabdomyolysis and its AKI risk, ongoing electrolyte swings, and DIC in severe cases. Crucially, the patient and family need to know this is a genetic condition: the patient should be counseled about MH-safe anesthesia for the future, referred for possible testing, and family members alerted that they may be susceptible too. This counseling and documentation piece is real, lasting patient safety.

What the nurse holds together

MH is the emergency you prepare for so you can move without hesitation: knowing where the dantrolene and MH cart live, recognizing rising end-tidal CO2 and rigidity as MH before the fever, pulling people into the room to reconstitute drug fast, running the cooling and the hyperkalemia response simultaneously, and then watching for recrudescence and protecting the kidneys afterward. It's rare enough that most nurses never see it — and preparation is exactly what makes the difference on the day one walks through the door. Related reading: serotonin syndrome vs NMS, rhabdomyolysis, hyperkalemia treatment, and cisatracurium (a non-triggering paralytic).